Hemanext ONE is the first meaningful FDA-authorized processing and storage technology proven to mitigate the red blood cell (RBC) storage lesion.1-4
Transforming Red Blood Cells 
Advancing Care.TM
Hemanext is a global biomedical technology pioneer in transfusion medicine. We recognize the vital role of blood for patients and are committed to optimizing its therapeutic impact and value to the healthcare system. Focused on the study of hypoxically stored RBCs, our research and development efforts aim to significantly improve the quality of stored RBCs worldwide. We strive to achieve our mission of delivering innovations that improve the standard of care for patients who rely on transfusions by transforming RBCs through protecting their quality, functionality, and viability during storage.
Latest News and Events
Hemanext signs agreements with healthcare distributor in the U.A.E.
Hemanext signs agreements with healthcare distributor in the U.A.E. to provide hospitals and clinicians with Hemanext ONE® system, marking the initiation of commercialization activities in the GCC LEXINGTON, Mass., October 29, 2024, PR NEWSWIRE – Hemanext Inc., a...
Hemanext Inc. Announces New HCPCS Code for “Red Blood Cells, Leukocytes Reduced, Oxygen/Carbon Dioxide Reduced, Each Unit.”
Hemanext Inc. Announces New HCPCS Code for “Red Blood Cells, Leukocytes Reduced, Oxygen/Carbon Dioxide Reduced, Each Unit.” LEXINGTON, Mass., September 9, 2024, – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, marks a...
Hemanext Inc. Announces Completion of Post-Market Cancer and Burn Safety Study
Hemanext Inc. Announces Completion of Post-Market Cancer and Burn Safety Study, a Significant Milestone for Hemanext ONE®, Hemanext’s Innovative Red Blood Cell (RBC) Processing and Storage System LEXINGTON, Mass., August 20, 2024, – Hemanext Inc., a leading innovator...
Hemanext Inc. Announces a Significant Milestone with FDA Marketing Authorization for Hemanext ONE®
Hemanext Inc. Announces a Significant Milestone with FDA Marketing Authorization for Hemanext ONE®, Hemanext’s Innovative Red Blood Cell (RBC) Processing and Storage System Hemanext ONE has been granted marketing authorization for commercial distribution via the De...
Hemanext Announces Founder Martin Cannon’s Retirement, Appoints Andrew Dunham as CEO, and Raises Funding for Growth
LEXINGTON, Mass., September 18, 2023, – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, marks a significant turning point in its history as the company announces the retirement of its founder, Martin Cannon. Simultaneously,...
Hemanext Research
Learn more about Hemanext and take a closer look at our publications, studies, and posters focused on blood quality and red blood cell characterization.